GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Connect Biopharma
Connect Biopharma is a biotech company developing drugs to treat autoimmune diseases. Its stock price is highly volatile and driven by news about the progress of its clinical trials.
Share prices of companies in the market segment - Pharma immune
Connect Biopharma is a biopharmaceutical company developing therapies for the treatment of chronic inflammatory diseases caused by T cells, such as atopic dermatitis. We classify it as an "Immune Pharmaceuticals" company. The chart below shows the dynamics of this segment.
Broad Market Index - GURU.Markets
Connect Biopharma is a biotech company developing drugs to treat chronic inflammatory diseases such as atopic dermatitis. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Connect shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
CNTB - Daily change in the company's share price Connect Biopharma
For Connect Biopharma, an immunology company, daily price change is a measure of extreme volatility. It reflects the market's reaction to clinical trial data and is a critical parameter for risk assessment formulas on the System.GURU.Markets platform.
Daily change in the price of a set of shares in a market segment - Pharma immune
For Connect Biopharma, an immunology company, daily price change is a measure of extreme volatility. It reflects the market's reaction to clinical trial data and is a critical parameter for risk assessment formulas on the GURU.Markets platform.
Daily change in the price of a broad market stock, index - GURU.Markets
Connect Biopharma is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Connect Biopharma
For Connect Biopharma, year-over-year performance is a story about developing drugs for the treatment of inflammatory diseases. Its 12-month market capitalization depends entirely on the clinical trial data for its lead candidate, which is being studied for atopic dermatitis. The success or failure of these studies has a dramatic impact on its valuation.
Annual dynamics of market capitalization of the market segment - Pharma immune
Connect Biopharma Holdings Limited is a clinical-stage biotechnology company developing drugs for the treatment of inflammatory diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Connect Biopharma is a clinical-stage biotech company whose fate depends on scientific breakthroughs, not the state of the economy. Its share price (ADR) reflects investor expectations for the success of new drug trials. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Connect Biopharma
Connect Biopharma is a clinical-stage biopharmaceutical company focused on treating inflammatory diseases. Its monthly performance directly reflects news from its clinical trials. Data from its drugs for the treatment of atopic dermatitis and asthma are key.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on developing treatments for T-cell inflammatory diseases. The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, one can assess the progress of its leading drugs for the treatment of atopic dermatitis and asthma in clinical trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Connect Biopharma is a biopharmaceutical company whose future depends on the results of clinical trials. Its shares don't move in sync with the market, but rather jump around after important news. The chart clearly demonstrates that the monthly fluctuations of CNTB are a reaction to internal events, not to overall investor sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Connect Biopharma
Connect Biopharma, a clinical-stage biotech developing therapies for autoimmune diseases, is experiencing high volatility. Weekly stock performance is driven by news about clinical trials and partnerships, reflecting the risks and potential in this competitive field.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Connect Biopharma develops therapies for autoimmune diseases. Shares of such companies are extremely sensitive to clinical trial results. This chart allows us to separate the unique dynamics associated with the company's news from the general sentiment in the pharmaceutical sector and assess its prospects.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Connect Biopharma is a clinical-stage biotech company. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that CNTB's performance is largely uncorrelated with the market, moving based on its own unique news.
Market capitalization of the company, segment and market as a whole
CNTB - Market capitalization of the company Connect Biopharma
Connect Biopharma's stock chart is a financial map of the fight against chronic inflammatory diseases. This biotech company's market cap reflects the hopes for its drugs for atopic dermatitis and asthma. Its volatility reflects the competitive environment and clinical trial results in one of the largest areas of pharmaceuticals.
CNTB - Share of the company's market capitalization Connect Biopharma within the market segment - Pharma immune
Connect Biopharma's market share in immunology reflects its focus on developing drugs for chronic inflammatory diseases. Its market share is based on the potential of its clinical programs targeting conditions such as atopic dermatitis, attracting the attention of investors in this competitive field.
Market capitalization of the market segment - Pharma immune
Connect Biopharma is a biotech company focused on treating inflammatory diseases. The chart below shows the overall market capitalization of this cutting-edge sector. Its dynamics reflect investors' high hopes for the development of new, more effective treatments.
Market capitalization of all companies included in a broad market index - GURU.Markets
Connect Biopharma is a biopharmaceutical company developing drugs for the treatment of autoimmune and inflammatory diseases. Its market capitalization reflects the potential of its research and development. The chart below shows the economic weight of early-stage companies.
Book value capitalization of the company, segment and market as a whole
CNTB - Book value capitalization of the company Connect Biopharma
For Connect Biopharma, book value represents its clinical research capital. The chart below shows its financial resources. This level is an indicator of the company's ability to fund the development of drugs for autoimmune diseases such as atopic dermatitis.
CNTB - Share of the company's book capitalization Connect Biopharma within the market segment - Pharma immune
Connect Biopharma is a clinical-stage biotech company developing therapeutics for immune diseases. Its value lies in its scientific platform and patents. Its share of tangible assets will be minimal, which is typical for R&D companies whose primary capital is intellectual property.
Market segment balance sheet capitalization - Pharma immune
Connect Biopharma is a clinical-stage biotech company. Its value is created in labs, not factories. This is a "lightweight" model. The chart below shows how much the biopharma industry as a whole relies on physical assets versus intellectual property.
Book value of all companies included in the broad market index - GURU.Markets
Connect Biopharma's assets represent capital invested in clinical trials of drugs for the treatment of chronic inflammatory diseases, such as atopic dermatitis. The book value reflects the financial resources devoted to this competitive but very large market.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Connect Biopharma
Connect Biopharma is a biotech company developing drugs to treat autoimmune diseases. Its balance sheet is cash for research. Its market capitalization reflects the potential of its candidate molecules in areas such as atopic dermatitis. The chart shows high volatility associated with clinical trial results.
Market to book capitalization ratio in a market segment - Pharma immune
Connect Biopharma is a biotech company developing therapies for inflammatory diseases. Its value is almost entirely dependent on clinical trial results. The chart shows how much its market capitalization, based on expectations, exceeds its book value.
Market to book capitalization ratio for the market as a whole
Connect Biopharma is a biotech company developing therapeutics for inflammatory diseases. The chart shows how the market values its scientific potential. The company's market capitalization reflects investors' bet on the success of its clinical trials, which could lead to the creation of new drugs for millions of patients, which is typical for innovative biotech companies.
Debts of the company, segment and market as a whole
CNTB - Company debts Connect Biopharma
Connect Biopharma is a clinical-stage biopharmaceutical company developing therapies for chronic inflammatory diseases. Debt is a strategic tool for such a company to finance late-stage clinical trials and prepare for potential commercial launch.
Market segment debts - Pharma immune
Connect Biopharma is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and inflammation. Their research targets key signaling pathways. The chart shows the financial norms for the biotech sector, against which Connect Biopharma, like its competitors, is raising capital to fund their long-term and expensive programs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Connect Biopharma
Connect Biopharma develops therapeutic molecules for the treatment of autoimmune diseases. The path from the lab to the pharmacy for such drugs is long and expensive. This chart shows the extent to which the company finances its clinical programs with debt. This is an important indicator of its financial vulnerability amid uncertain research results.
Market segment debt to market segment book capitalization - Pharma immune
Developing drugs to treat autoimmune diseases and allergies, like Connect Biopharma's, requires lengthy and expensive clinical trials. This chart shows how the biotech sector as a whole funds R&D. It allows one to evaluate the company's financial model and its reliance on external capital to advance its molecules compared to the industry average.
Debt to book value of all companies in the market
Connect Biopharma develops therapies for chronic inflammatory diseases. The path from scientific idea to approved drug is long and requires significant capital investment. The chart helps understand how their debt burden, required for clinical trials, compares to the overall level of leverage in the market.
P/E of the company, segment and market as a whole
P/E - Connect Biopharma
This chart shows the valuation of Connect Biopharma, a biopharmaceutical company specializing in the treatment of autoimmune diseases. For a clinical-stage company, its value is determined by investor expectations for the success of its drugs. The chart reflects hopes for the development of new, effective therapies.
P/E of the market segment - Pharma immune
This metric represents the average valuation for the biotech sector in which Connect Biopharma operates. In this industry, filled with research-stage companies, the average earnings estimate is often uninformative. However, it does reflect the overall level of investor optimism regarding autoimmune disease treatments.
P/E of the market as a whole
Connect Biopharma is a biotech company developing drugs to treat autoimmune and inflammatory diseases, such as atopic dermatitis. Its valuation is dependent on clinical trial results. This chart shows the overall interest in immunology. It allows you to compare how the market views the potential of Connect Biopharma's drugs against existing blockbusters from major pharmaceutical companies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Connect Biopharma
Connect Biopharma is a biotech company developing therapies for the treatment of T-cell-mediated inflammatory diseases such as atopic dermatitis and ulcerative colitis. Its future depends on the success of its lead candidates in clinical trials. This chart shows how investors assess the potential of its drugs to capture market share in major chronic inflammatory disease markets.
%20P%2FE%20Connect%20Biopharma&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Connect-Biopharma&v=1772586275475 "Chart of the company's future (projected) P/E Connect Biopharma")
Future (projected) P/E of the market segment - Pharma immune
Connect Biopharma is a biotech company developing drugs to treat autoimmune and inflammatory diseases. Its research targets key signaling molecules in the immune system. This chart reflects expectations for the biotech sector, allowing one to assess the market's perception of Connect Biopharma's scientific potential and clinical pipeline.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772586275494 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Connect Biopharma is a biotech company developing therapies for T-cell inflammatory diseases such as atopic dermatitis. Their pricing depends on clinical trial results. This chart of overall expectations shows investor risk appetite. Market optimism facilitates funding for expensive research targeting large markets.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772586275514 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Connect Biopharma
Connect Biopharma is a clinical-stage biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. This chart shows the cost of advancing drugs through late-stage clinical trials. Future profits depend on positive results and subsequent regulatory approval.
Profit of companies in the market segment - Pharma immune
Swvl Holdings Corp. is a ridesharing technology solutions provider operating in emerging markets. Its profitability depends on its ability to optimize routes and achieve scale. This chart highlights the challenges in the smart mobility sector, where competition, regulatory barriers, and high operating costs make the path to profitability very difficult.
Overall market profit
Connect Biopharma is a biotech company developing drugs to treat autoimmune and inflammatory diseases. Currently in clinical trials, its value is determined by its scientific potential and research results. It's an example of a business that can either rise or fall after the publication of key data, regardless of the economic climate.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Connect Biopharma
Connect Biopharma is a biotechnology company developing drugs for the treatment of autoimmune and inflammatory diseases. Its revenue forecast depends on the results of clinical trials of its lead candidates. This chart reflects analyst expectations regarding the potential of these drugs and the company's ability to bring them to commercialization.
%20profit%20of%20the%20company%20Connect%20Biopharma&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Connect-Biopharma&v=1772586275787 "Graph of future (projected) profit of the company Connect Biopharma")
Future (predicted) profit of companies in the market segment - Pharma immune
Connect Biopharma is a clinical-stage biopharmaceutical company developing drugs for the treatment of autoimmune and inflammatory diseases, such as atopic dermatitis. This chart shows profitability forecasts for the biotech sector. It reflects the high expectations and high risks associated with bringing new drugs to market for chronic diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772586275937 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Connect Biopharma develops therapeutic drugs for the treatment of autoimmune and inflammatory diseases. Like many biotech companies, its future depends on the results of clinical trials. However, the overall corporate earnings forecast, illustrated by this chart, shapes the investment climate and influences the company's valuation when seeking partners or raising capital.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772586276002 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Connect Biopharma
Connect Biopharma is a biotech company developing therapies for the treatment of T-cell inflammatory diseases such as atopic dermatitis. Being in the clinical stage, it has not yet generated commercial revenue. The valuation in this chart is based entirely on investor expectations regarding the success of its clinical trials and the future market potential of its drugs.
P/S market segment - Pharma immune
Connect Biopharma is a clinical-stage biopharmaceutical company developing treatments for T-cell-mediated inflammatory diseases such as atopic dermatitis and asthma. This chart shows the average valuation in the sector, allowing one to assess the market's perception of the revenue potential of Connect Biopharma's immunology developments.
P/S of the market as a whole
Connect Biopharma is a biopharmaceutical company developing drugs for the treatment of autoimmune and inflammatory diseases. Its key developments are focused on atopic dermatitis and asthma. This chart, reflecting the average estimated real revenue, clearly highlights how biotech investments are betting on scientific breakthroughs in immunology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Connect Biopharma
Connect Biopharma develops therapeutic drugs for the treatment of autoimmune and inflammatory diseases. This chart illustrates how investors assess the future potential of its development pipeline. The assessment is based on expectations of successful clinical trial results, which could lead to the development of new, effective drugs.
%20P%2FS%20Connect%20Biopharma&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Connect-Biopharma&v=1772586276060 "The graph of the company's future (projected) P/S Connect Biopharma")
Future (projected) P/S of the market segment - Pharma immune
Connect Biopharma is a biopharmaceutical company developing drugs to treat autoimmune and inflammatory diseases, such as atopic dermatitis and ulcerative colitis. This chart shows the premium investors are willing to pay for Connect Biopharma's future sales, reflecting the potential of its developments in major pharmaceutical markets.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772586276077 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Future revenue expectations in biotech depend on progress in treating autoimmune and inflammatory diseases. Connect Biopharma develops drugs for conditions such as atopic dermatitis. The potential of its drugs to improve the quality of life for millions of patients supports investor confidence in the long-term growth prospects of this therapeutic segment.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772586276101 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Connect Biopharma
Connect Biopharma is a clinical-stage biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. Currently, the company has no revenue from product sales, and its cash flow reflects revenue from potential licensing agreements and collaborations that fund its research.
Sales of companies in the market segment - Pharma immune
Connect Biopharma is a biopharmaceutical company developing treatments for chronic inflammatory diseases such as atopic dermatitis and ulcerative colitis. This chart reflects overall revenue in the immunology pharmaceutical sector. It highlights the vast and growing market for drugs that could improve the lives of millions of patients with autoimmune disorders.
Overall market sales
Connect Biopharma is a clinical-stage biopharmaceutical company developing therapies for T-cell-mediated inflammatory diseases such as atopic dermatitis. Its prospects depend on the success of clinical trials. This overall economic climate influences investor willingness to invest in long-term, capital-intensive biotech projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Connect Biopharma
Connect Biopharma is a biopharmaceutical company developing therapies for T-cell inflammatory diseases such as atopic dermatitis. Its future depends on the success of clinical trials. The chart shows analysts' speculative forecasts, which are bets that the company will be able to offer an effective treatment for these common conditions.
%20sales%20of%20the%20company%20Connect%20Biopharma&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Connect-Biopharma&v=1772586276240 "Schedule of future (projected) sales of the company Connect Biopharma")
Future (projected) sales of companies in the market segment - Pharma immune
Connect Biopharma is a biopharmaceutical company developing drugs to treat autoimmune and inflammatory diseases, such as atopic dermatitis. The company's success depends on the results of clinical trials. This chart shows projected sales for the entire immunological pharmaceutical segment, demonstrating overall growth expectations for this medical field.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772586276249 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Connect Biopharma is a clinical-stage biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. Its value is determined by the potential of its lead candidates. This overall economic activity profile influences the investment climate and the willingness of large pharma companies to enter into partnerships, which are critical for such companies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772586276273 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Connect Biopharma
Connect Biopharma is a biotechnology company developing therapeutics for inflammatory diseases. This metric reflects its financial progress through the clinical trials stage. It demonstrates the level of investment in research and development, which forms the basis for developing a new class of drugs and reaching the commercial stage.
Market segment marginality - Pharma immune
Connect Biopharma is a clinical-stage biopharmaceutical company developing drugs for the treatment of autoimmune and inflammatory diseases. Its financial metrics reflect intensive investment in R&D. This chart helps evaluate the company's operational structure and cost profile compared to other immunology companies.
Market marginality as a whole
Connect Biopharma is a clinical-stage biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. Their drugs target T-cell modulation. Their future depends on the success of clinical trials. This overall profitability curve is important to them only in terms of the overall investment climate in the biotech sector.
Employees in the company, segment and market as a whole
Number of employees in the company Connect Biopharma
Connect Biopharma is a clinical-stage biotech company focused on treating autoimmune diseases. Its core is its scientific team. This chart shows how the company is expanding its staff to conduct increasingly large and expensive clinical trials of its drug candidates, targeting multi-billion dollar markets.
Share of the company's employees Connect Biopharma within the market segment - Pharma immune
Connect Biopharma develops therapies for T-cell inflammatory diseases. This chart shows the percentage of leading immunologists specializing in this signaling pathway that the company attracts. Its team is at the forefront of research in finding new approaches to treating atopic dermatitis and asthma.
Number of employees in the market segment - Pharma immune
Connect Biopharma Holdings is a clinical-stage biopharmaceutical company developing therapies for chronic inflammatory diseases. This chart shows overall employment in the immunology research sector. It illustrates the active pursuit of new drugs for immune-related diseases and the intense competition in this field.
Number of employees in the market as a whole
Connect Biopharma is a clinical-stage biotechnology company developing therapies for chronic T-cell-mediated inflammatory diseases. This is a promising area of medicine. This employment chart reflects the contribution of research-intensive companies, whose growth requires the involvement of highly qualified scientists and physicians to conduct complex clinical trials.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Connect Biopharma (CNTB)
Connect Biopharma is a clinical-stage biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. This chart is a prime example of biotech. The high market capitalization per employee indicates that the market appreciates the potential of the drugs being developed by a small but highly qualified scientific team.
%20of%20the%20company%20Connect%20Biopharma%20(CNTB)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Connect-Biopharma-CNTB&v=1772586276643 "Chart of market capitalization per employee (in thousands of dollars) of the company Connect Biopharma (CNTB)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Connect Biopharma is a clinical-stage biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. Their valuation is entirely dependent on the potential of their developments. This metric demonstrates the enormous value the market places on their scientific pipeline, based on a small team of highly qualified researchers.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772586276738 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Connect Biopharma is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases. Its valuation is entirely dependent on the outcome of clinical trials. This metric illustrates how investors evaluate scientific potential, where a single drug breakthrough can create a multi-billion-dollar company.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772586276783 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Connect Biopharma (CNTB)
Connect Biopharma is a clinical-stage biotech R&D company developing therapies for autoimmune diseases (e.g., atopic dermatitis). This chart shows their capital burn rate—the net loss (costs of clinical trials) per employee.
%20Chart%20Connect%20Biopharma%20(CNTB)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Connect-Biopharma-CNTB&v=1772586276846 "Company Profit Per Employee (in thousands of dollars) Chart Connect Biopharma (CNTB)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Connect Biopharma is a clinical-stage biotech focused on treating autoimmune diseases. Like most biotechs in the R&D phase, this metric is currently negative. This chart provides a guide to the future. Success will depend on whether their scientific team can create a drug that delivers profitability above the industry standard.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772586276890 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Connect Biopharma (CNTB) is a clinical-stage biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. Their business is scientific research. This chart shows a typical biotech picture: negative profit per employee, as all resources are invested in clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772586276955 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Connect Biopharma (CNTB)
For Connect Biopharma, a company developing therapies for autoimmune and inflammatory diseases, this graph reflects progress in clinical trials. Revenue per employee likely comes from partnerships, and its growth depends on the success of bringing new drugs to market.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Connect-Biopharma-CNTB&v=1772586277031 "Sales chart per company employee Connect Biopharma (CNTB)")
Sales per employee in the market segment - Pharma immune
Connect Biopharma is a clinical-stage biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. This is R&D. This metric reflects the average revenue per employee in the segment. It helps assess how productive their scientific team is in advancing their candidates to the clinic compared to other immunology biotechs.
Sales per employee for the market as a whole
Connect Biopharma (CNTB) is a clinical-stage biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. Currently, its staff consists entirely of researchers. This metric is critical for CNTB: it's at zero. Future growth will depend on either successful licensing of their candidates or partnerships.
Short shares by company, segment and market as a whole
Shares shorted by company Connect Biopharma (CNTB)
Connect Biopharma is a clinical-stage biotech focused on treating autoimmune diseases. Its shares have plummeted following mixed trial results. This chart shows how many investors are betting that its lead drug has no commercial prospects and that its remaining projects in development will also fail.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Connect-Biopharma-CNTB&v=1772586277265 "Short Shares Chart for the Company Connect Biopharma (CNTB)")
Shares shorted by market segment - Pharma immune
Connect Biopharma (CNTB) is a biopharmaceutical company developing therapies for T-cell inflammatory diseases such as atopic dermatitis and asthma. This chart summarizes the bearish bets on the immunobiotech sector. It shows the overall market pessimism regarding the high level of competition and failure rates in this field.
Shares shorted by the overall market
Connect Biopharma (CNTB) is a clinical-stage biotech company. Its value is based on future expectations. When this market fear indicator rises, investors' risk appetite evaporates. They are the first to sell speculative, unprofitable biotechs like CNTB.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Connect Biopharma (CNTB)
Connect Biopharma (CNTB) is a biotech company working in the competitive field of immunology (e.g., atopic dermatitis). This is a high-risk bet on their R&D. This chart measures the extremes of speculative sentiment. It shows when the stock is "overbought" on positive data or "oversold" on news of setbacks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Connect-Biopharma-CNTB&v=1772586277493 "RSI 14 indicator chart for the company's stock Connect Biopharma (CNTB)")
RSI 14 Market Segment - Pharma immune
Connect (CNTB) is a biotech (China/USA) stock that targets immune diseases (dermatitis, asthma). The Pharma-Immune (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand whether CNTB's growth is due to its R&D or whether the entire biotech sector is simply overheated by expectations.
RSI 14 for the overall market
Connect Biopharma (CNTB) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CNTB (Connect Biopharma)
Connect Biopharma is a biopharmaceutical company developing T-cell modulation therapies for autoimmune and inflammatory diseases, such as atopic dermatitis. This chart shows the speculative average price target from analysts based on their assessment of this R&D portfolio.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CNTB-Connect-Biopharma&v=1772586277604 "A chart showing analyst consensus forecasts for the expected stock price. CNTB (Connect Biopharma)")
The difference between the consensus estimate and the actual stock price CNTB (Connect Biopharma)
CNTB - Connect Biopharma is a biotech company developing antibody-based therapies for severe chronic inflammatory diseases. This chart shows how the current share price differs from the "fair" value predicted by analysts. It reflects their confidence in the company's R&D portfolio and its chances of clinical success.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CNTB-Connect-Biopharma&v=1772586277645 "A chart showing the difference between the consensus forecast and the actual stock price. CNTB (Connect Biopharma)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Connect Biopharma (CNTB) is a biotech company developing drugs to treat autoimmune and inflammatory diseases (atopic dermatitis, asthma). This chart shows analysts' overall expectations for the immunopharma sector. It reflects whether experts believe R&D success in this competitive field.
Analysts' consensus forecast for the overall market share price
Connect Biopharma is a biotech company specializing in developing drugs to treat autoimmune and inflammatory diseases (atopic dermatitis). This chart shows the overall risk appetite. For Connect, a high-risk clinical-stage company, overall market optimism is critical to attracting the capital needed to fund long-term research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Connect Biopharma
Connect (CNTB) is a clinical-stage biotech focused on immunology. They are developing drugs to treat chronic inflammatory diseases (atopic dermatitis, asthma). This graph represents pure R&D betting. Its valuation reflects the market's faith in their scientific platform and the (very risky) data from their clinical trials.
AKIMA Market Segment Index - Pharma immune
Connect Biopharma is a clinical-stage company developing therapies for autoimmune and inflammatory diseases, such as atopic dermatitis. This chart shows the average index for the immunopharmaceutical sector. It provides investors with a benchmark for how Connect Biopharma's performance compares to the sector average.
The AKIM Index for the overall market
Connect Biopharma is a global biopharmaceutical company developing immunomodulators for the treatment of inflammatory diseases (such as dermatitis). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this late-stage company compares to overall economic trends in biotech.
